Meanwhile, the BSE Sensex was down 283.04 points, or 1.54% to 18,145.57.
On BSE, 43,465 shares were traded in the counter as against average daily volume of 43,683 shares in the past one quarter.
The stock hit a high of Rs 39.30 and a low of Rs 36.40 so far during the day. The stock had hit a 52-week low of Rs 26.10 on 21 December 2011. The stock had hit a 52-week high of Rs 62.50 on 16 November 2011.
The small-cap stock had outperformed the market over the past one month till 21 February 2012, rising 24.01% compared with the Sensex's 10.09% gain. The scrip had, however, underperformed the market in past one quarter, falling 19.98% as against Sensex's 15.57% gain.
The company has an equity capital of Rs 65.77 crore. Face value per share is Rs 10.
The Transgene Biotek stock has surged 16.04% in four trading sessions from a recent low of Rs 32.40 on 15 February 2012, after the company announced stellar Q3 earnings after market hours on 15 February 2012.
Transgene Biotek's net profit galloped 31360% to Rs 15.73 crore on 762.6% growth in net sales to Rs 8.54 crore in Q3 December 2011 over Q3 December 2010. The company said that there was exceptional income of Rs 13.09 crore in Q3 December 2011, which represents gain due to foreign exchange fluctuations.
Transgene Biotek is engaged in the research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for the qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.